Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB15 vs Eylea in Neovascular AMD
NCT04450329Phase 3Completed
- Sponsor
- Samsung Bioepis
- Start
- Jun 2020
- Primary completion
- Apr 2021
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 10
01
Overview
A Phase 3 trial of aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Samsung Bioepis. Started Jun 2020; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04450329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04450329.